Journal
CHEMMEDCHEM
Volume 7, Issue 9, Pages 1647-1660Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201200272
Keywords
cyclooxygenase; inflammation; medicinal chemistry; multitarget drugs; thromboxane
Categories
Funding
- Regione Lombardia (Progetto Ex-ASTIL) [16755-Rif. SAL-02]
- Fondazione Banca del Monte di Lombardia
- MIUR Grand (COFIN)
Ask authors/readers for more resources
A series of lumiracoxib derivatives were designed to explore the influence of isosteric substitution on balancing COX-2 inhibition and thromboxane A2 prostanoid (TP) receptor antagonism. The compounds were synthesized through a copper-catalyzed coupling procedure and characterized for their pKa values. TP receptor antagonism was assessed on human platelets; COX-2 inhibition was determined on human isolated monocytes and human whole blood. TPa receptor binding of the most promising compounds was evaluated through radioligand binding assays. Some of the isosteric substitutions at the carboxylic acid group afforded compounds with improved TP receptor antagonism; of these, a tetrazole derivative retained good COX-2 inhibitory activity and selectivity. The identification of this tetrazole acting as a balanced dual-acting compound in human whole blood, along with SAR analysis of the synthesized lumiracoxib derivatives, might contribute to the rational design of a new class of cardioprotective anti-inflammatory agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available